首页> 美国卫生研究院文献>Pharmaceutics >Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab
【2h】

Assessment of In-Situ Gelling Microemulsion Systems upon Temperature and Dilution Condition for Corneal Delivery of Bevacizumab

机译:贝伐单抗角膜递送温度和稀释条件对原位胶凝微乳液系统的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bevacizumab (BVZ), a recombinant humanized monoclonal antibody, has recently been proposed as a topical application in the treatment of anterior segment neovascularization; however, as there are some disadvantages in the administration of common eye-drops, ophthalmic topical drug delivery systems are under study to improve the precorneal residence time, reducing the frequency of administration. In this work, oil-in-water and water-in-oil BVZ-loaded microemulsions are developed, able to increase their viscosity, either by the formation of a liquid-crystalline structure upon aqueous dilution, thanks to the presence of Epikuron® 200 and polysorbate 80, or by body-temperature-induced jellification for the presence of Pluronic® F127 aqueous solution as an external phase. In oil-in-water microemulsion, hydrophobic ion pairs of BVZ were also prepared, and their incorporation was determined by release studies. Microemulsions were characterized for rheological behavior, corneal opacity, in vitro corneal permeation, and adhesion properties. The studied microemulsions were able to incorporate BVZ (from 1.25 to 1.6 mg/mL), which maintained dose-dependent activity on retinal pigment epithelial ARPE-19 cell lines. BVZ loaded in microemulsions permeated the excised cornea easier (0.76–1.56% BVZ diffused, 4–20% BVZ accumulated) than BVZ commercial solution (0.4% BVZ diffused, 5% accumulated) and only a mild irritation effect on the excised cornea was observed. The good adhesion properties as well the increased viscosity after application, under conditions that mimic the corneal environment (from 1 × 103 to more than 100 × 103 mPa·s), might prolong precorneal residence time, proving these systems could be excellent topical BVZ release systems.
机译:Bevacizumab(BVZ)是一种重组人源化单克隆抗体,最近被提出为治疗前段新血管形成的局部应用;然而,由于常见眼药施用存在一些缺点,因此正在研究眼科局部药物递送系统以改善前甲型停留时间,降低给药频率。在这项工作中,通过在水性稀释时形成液晶结构,可以通过在水性稀释时形成粘度,通过在水性稀释时形成粘度,通过在稀释剂上形成液晶结构来增加水 - 水和油状的BVZ的微乳液。和聚山梨醇酯80,或通过体温诱导的果冻,用于作为外部阶段存在Pluronic®F127水溶液。在水包油微乳液中,还制备了疏水离子对BVZ,并通过释放研究确定了它们的掺入。微乳液的特征在于流变行为,角膜不透明度,体外角膜渗透和粘附性。研究的微乳液能够包含BVZ(从1.25-1.6mg / ml),在视网膜颜料上皮ARPE-19细胞系上保持剂量依赖性活性。在微乳液中装载的BVZ渗透切除的角膜更容易(0.76-1.56%BVZ扩散,累积4-20%BVZ)比BVZ商业溶液(0.4%BVZ扩散,累积5%),观察到对切口角膜的轻度刺激作用。良好的粘合性能也增加了施用后的粘度增加,在模拟角膜环境(从1×103到100×103MPa·s)的条件下,可能会延长前居住地,证明这些系统可能是出色的局部BVZ释放系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号